Piper Jaffray Companies Analysts Give OptiNose (OPTN) a $28.00 Price Target

Piper Jaffray Companies set a $28.00 target price on OptiNose (NASDAQ:OPTN) in a research report report published on Monday morning. The brokerage currently has a buy rating on the stock.

Several other brokerages have also recently weighed in on OPTN. BMO Capital Markets started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued an outperform rating and a $29.00 price objective on the stock. Jefferies Group started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued a buy rating and a $27.00 price objective on the stock. Finally, Royal Bank of Canada started coverage on shares of OptiNose in a research note on Tuesday, November 7th. They issued an outperform rating and a $33.00 price objective on the stock.

Shares of OptiNose (NASDAQ OPTN) opened at $19.10 on Monday. OptiNose has a one year low of $15.01 and a one year high of $21.50.

OptiNose (NASDAQ:OPTN) last posted its earnings results on Monday, November 27th. The company reported ($4.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($3.76). equities research analysts anticipate that OptiNose will post -1.49 earnings per share for the current year.

A hedge fund recently bought a new stake in OptiNose stock. Schwab Charles Investment Management Inc. purchased a new stake in shares of OptiNose Inc (NASDAQ:OPTN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 22,854 shares of the company’s stock, valued at approximately $432,000. Schwab Charles Investment Management Inc. owned about 0.06% of OptiNose at the end of the most recent quarter.

WARNING: “Piper Jaffray Companies Analysts Give OptiNose (OPTN) a $28.00 Price Target” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2018/01/18/piper-jaffray-companies-analysts-give-optinose-optn-a-28-00-price-target.html.

OptiNose Company Profile

OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply